THE ROLE OF GENOMIC SCREENING IN TRANSFORMING PUBLIC HEALTH Understanding ethical, legal & social impacts of genomic screening
With
Dr Jane Tiller, Ethical, Legal & Social Adviser,
Public Health Genomics, Monash University
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Melbourne | July 2025
Dr Jane Tiller is a lawyer, genetic counsellor and public health researcher. She is Ethical, Legal & Social Adviser in Public Health Genomics at Monash University, and a National Health and Medical Research Council Investigator Grant holder. Jane is passionate about the use of genomics to prevent disease, and in delivering equitable access to preventive genetic information at the population level. She is co-lead of DNA Screen, a world-first study piloting the offer of preventive DNA screening to the Australian adult population. DNA Screen has tested over 10,000 young people for genetic high risk of medically actionable conditions such as cancer and heart disease, finding about 2% of participants had genetic high risk. Jane is leading efforts to secure Commonwealth Government funding to expand the DNA Screen program, with the eventual goal of the development of a public health population screening program for disease prevention based on high genetic risk.
Jane also focusses on identifying and addressing the ethical, legal and social barriers to public acceptability and uptake of genetic screening. She co-founded the Australian Genetic Non-Discrimination Working Group, and led a project from 2020-2023 about genetic discrimination in life insurance. Jane led significant advocacy efforts towards translating her research findings into real world policy change. She was instrumental in the Government’s 2024 announcement that it will legislate a total ban on the use of genetic results in life insurance underwriting. Jane’s work has been recognised through a number of competitive awards, including recently the prestigious 2024 Research Australia Advocacy Award.
Source: Supplied
-
New option for management of high-risk soft tissue sarcoma of the limb
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
-
Surgical Site Infection (SSI) Synopsis, including modifiable and non-modifiable risk factors
Talking to the Australian Health Journal, Professor Russo states there is a particular concern in joint operations, such as hip or knee replacements, as infections in these areas can have severe consequences, including the removal of the infected joint, prolonged treatment, and significant costs for both hospitals and patients. Despite the substantial impact of surgical site infections, Australia lacks a national surveillance program for these infections, making it challenging to obtain accurate data. However, an estimate suggests that around 45,000 surgical site infections occur annually in Australia, resulting in approximately 900 deaths.
-
Analogy of the system, rather than the ED front door
“The problem of blockages shows up in ambulance ramping and long wait times, but this is a complex issue requiring whole-of-health system solutions,” according to Professor Hugh Grantham, Chair of Emergency Medicine Foundation in an interview with Australian Health Journal.
